Evidence map›Paper›PMID 15815684›Full record

ArticleEMBO reports2005

FtsY, the bacterial signal-recognition particle receptor, interacts functionally and physically with the SecYEG translocon.

Sandra Angelini, Sandra Deitermann, Hans-Georg Koch

Open access · bronzeAbstract read
In one paragraph

Article in EMBO reports, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 144 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. The Dynamic SecYEG Translocon.Frontiers in molecular biosciences · 2021
    Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. UnravelingFrontiers in microbiology · 2018
    Article
  16. Environmental adaptation ofInternational journal of biological sciences · 2018
    Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Sandra AngeliniInstitute for Biochemistry & Molecular Biology, University Freiburg, Hermann-Herder-Strasse 7, 79104 Freiburg, Germany.
Sandra Deitermann
Hans-Georg Koch
University of Freiburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Co-translational membrane targeting of proteins by the bacterial signal-recognition particle (SRP) requires the specific interaction of the SRP-ribosome nascent chain complex with FtsY, the bacterial SRP receptor (SR). FtsY is homologous to the SRalpha-subunit of the eukaryotic SR, which is tethered to the endoplasmic-reticulum membrane by its interaction with the integral SRbeta-subunit. In contrast to SRalpha, FtsY is partly membrane associated and partly located in the cytosol. However, the mechanisms by which FtsY associates with the membrane are unclear. No gene encoding an SRbeta homologue has been found in bacterial genomes, and the presence of an FtsY-specific membrane receptor has not been shown so far. We now provide evidence for the direct interaction between FtsY and the SecY translocon. This interaction offers an explanation of how the bacterial SRP cycle is regulated in response to available translocation channels.

Indexed as

Bacterial ProteinsCell MembraneEscherichia coliEscherichia coli ProteinsMutationProtein BindingProtein Structure, TertiaryReceptors, Cytoplasmic and NuclearSEC Translocation ChannelsSignal Recognition ParticleBacterial ProteinsEscherichia coli ProteinsFtsY protein, BacteriaReceptors, Cytoplasmic and NuclearSEC Translocation ChannelsSecY protein, E coliSignal Recognition Particle

Identifiers

PMID15815684
PMCPMC1299298
OpenAlexW2133613174

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.